Sandra Chaparro, MD, makes the case for SGLT2 inhibitors across a broad spectrum of chronic kidney disease, even in patients without diabetes.
Sandra Chaparro, MD
Advertisement
Sandra Chaparro, MD, director of Advanced Heart Failure at Miami Cardiac & Vascular Institute, part of Baptist Health South Florida.
Articles by Sandra Chaparro, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
3
Childhood Influenza Vaccine Rates Decreased From 2017 to 2023
4
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
5